Prognostic Factors in Brain Tumours
Author Information
Author(s): E. Jaros, R.H. Perry, L. Adam, P.J. Kelly, P.J. Crawford, R.M. Kalbag, A.D. Mendelow, R.P. Sengupta, A.D.J. Pearson
Primary Institution: Newcastle General Hospital
Hypothesis
The study aims to correlate the expression of mutant p53 protein and EGFR with tumour proliferative activity and patient outcomes in CNS tumours.
Conclusion
The expression of p53 mutants and EGFR in astrocytomas is associated with increased malignancy and poorer patient survival.
Supporting Evidence
- Patients with p53 positive astrocytomas had only 11% survival at 100 weeks compared to 36% for p53 negative.
- EGFR positive patients had a 13% survival rate at 100 weeks compared to 60% for EGFR negative patients.
- Ki-67 LI greater than 5% was associated with no survival beyond 86 weeks.
Takeaway
This study looked at brain tumours and found that certain proteins can help predict how aggressive the cancer is and how long patients might live.
Methodology
The study examined 78 CNS tumours using immunohistochemistry to assess the expression of p53, EGFR, and Ki-67.
Limitations
The study's findings may not apply to all types of brain tumours due to the specific focus on astrocytomas and the limited sample size for some analyses.
Participant Demographics
The study included patients with various types of CNS tumours, primarily astrocytomas.
Statistical Information
P-Value
P = 0.035 and P = 0.007 for p53 and EGFR respectively; P<0.0001 for Ki-67.
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website